Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases
about
The Role of Damage-Associated Molecular Patterns in Human Diseases: Part I - Promoting inflammation and immunityU1-RNP and TLR receptors in the pathogenesis of mixed connective tissue diseasePart I. The U1-RNP complex and its biological significance in the pathogenesis of mixed connective tissue diseaseDeregulation of innate immune and inflammatory signaling in myelodysplastic syndromesSex Differences in monocytes and TLR4 associated immune responses; implications for systemic lupus erythematosus (SLE)Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy.The parasitic worm product ES-62 targets myeloid differentiation factor 88-dependent effector mechanisms to suppress antinuclear antibody production and proteinuria in MRL/lpr miceTherapeutic Developments Targeting Toll-like Receptor-4-Mediated NeuroinflammationTissue-specific mRNA expression profiles of porcine Toll-like receptors at different ages in germ-free and conventional pigs.Drug-like analogues of the parasitic worm-derived immunomodulator ES-62 are therapeutic in the MRL/Lpr model of systemic lupus erythematosusIncreased activation of toll-like receptors-7 and -8 of peripheral blood mononuclear cells and upregulated serum cytokines in patients with pediatric systemic lupus erythematosusU1-RNP and Toll-like receptors in the pathogenesis of mixed connective tissue diseasePart II. Endosomal TLRs and their biological significance in the pathogenesis of mixed connective tissue disease.Whole-genome transcription and DNA methylation analysis of peripheral blood mononuclear cells identified aberrant gene regulation pathways in systemic lupus erythematosus.The complement receptor 3 (CD11b/CD18) agonist Leukadherin-1 suppresses human innate inflammatory signalling.Drugs in early clinical development for Systemic Lupus Erythematosus.Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.Emerging roles of innate immune signaling and toll-like receptors in fibrosis and systemic sclerosis.Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain.A Plasmacytoid Dendritic Cells-Type I Interferon Axis Is Critically Implicated in the Pathogenesis of Systemic Lupus Erythematosus.What can we learn from systemic lupus erythematosus pathophysiology to improve current therapy?Intramembrane attenuation of the TLR4-TLR6 dimer impairs receptor assembly and reduces microglia-mediated neurodegeneration.Update on the role of plasmacytoid dendritic cells in inflammatory/autoimmune skin diseases.Innate immunity in Sjögren's syndrome.Protein Tyrosine Phosphatases in Systemic Sclerosis: Potential Pathogenic Players and Therapeutic Targets.Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics.The development of antimicrobial a-AApeptides that suppress proinflammatory immune responses.Use of lipolanthionine peptide, a toll-like receptor 2 inhibitor, enhances transdermal delivery efficiencyToll-Like Receptor-4 Signaling Drives Persistent Fibroblast Activation and Prevents Fibrosis Resolution in Scleroderma.TLR-Induced SMPD3 Defects Enhance Inflammatory Response of B Cell and Macrophage in the Pathogenesis of SLE.Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation.Small Molecule Analogues of the parasitic worm product ES-62 interact with the TIR domain of MyD88 to inhibit pro-inflammatory signalling.Gut Microbiota and Type 1 Diabetes.Increased expression of TLR2 in CD4(+) T cells from SLE patients enhances immune reactivity and promotes IL-17 expression through histone modifications.Activation of TLR9-dependent p38MAPK pathway in the pathogenesis of primary Sjögren's syndrome in NOD/Ltj mouse.Attenuation of berberine on lipopolysaccharide-induced inflammatory and apoptosis responses in β-cells via TLR4-independent JNK/NF-κB pathway.Role of Microglia TLRs in Neurodegeneration
P2860
Q26864215-FFB35687-1BA4-49AF-ACC9-F014DDA2A523Q27006881-E0899500-41DB-4CA8-8B53-08496AFC97DFQ27015288-41603CB2-6FA3-456B-9A4E-CC22B31B9F27Q34323715-D2211450-2744-4409-97EC-84D53585537FQ34750515-3FBBAE43-5E11-4D10-B07A-674086CAFF20Q35538362-EB04DF4A-9A5D-4D8B-8F85-DB0BC50BE0F4Q35681383-F4EA0D71-C6D0-4696-A254-59019CC67061Q35953024-F81458D5-6DDA-4D93-BF37-BAF65C460A64Q36196097-CCEC9BAF-890B-408D-8FC5-54D66CFAB71EQ36492750-FCE4EA8D-EC2D-4470-9524-3EC62ECDA808Q36842417-2CDBDB93-8583-4618-909B-EA0BE4120A74Q37089938-1A18F6CE-2E57-4ED5-8598-ECADFD1F1126Q37190531-BFF9BAED-C1A6-4D6D-BF7F-FBAFD5CA7F05Q37324772-F17B8245-8BA1-473F-855E-3874A7B46240Q38150110-C646B44A-4002-4019-9C51-4D21A6256F52Q38325712-F00B36E7-02DB-4061-BCB6-4729B566285AQ38395503-EA324F87-C8DF-4EF2-B29A-218B30C0EC9DQ38537618-5ABBAAA8-A42C-44B9-B429-BF4A1EF9FC50Q38590248-579D646D-042B-4827-9AB4-B6712CE6A57DQ38698825-1693A522-A78F-4885-87B4-04CBD862FBF7Q38720050-6A1E5613-8867-4D6A-A6A9-AD91825389A3Q39232871-2DA73175-21A0-4312-9063-8CF2978CFBB7Q39233347-493E0A7B-6FE2-47BF-826D-38461EECCEDAQ39293951-E0FAF2E9-81D5-480C-AD60-07860AF10BBCQ40251304-C5F43AD1-46A9-498C-A554-AE53A8D0177CQ42733178-69DD910C-F881-45C5-9338-CDBFA6C41CDFQ47095125-8FF696EF-5813-4A63-B8E3-8C16C7A5B7BAQ47826879-C19F757E-AB36-4972-8225-DB31C6293FE1Q48089641-8F095C74-087E-4E15-B104-79B5DBE6833EQ48120789-840E654B-736C-4F4F-894E-DA2EE62BC851Q51144461-36997D39-363A-4AFE-96FC-53A783188D71Q52936645-3FFC25FF-7C8E-49AA-81B2-80D0E5A2F76CQ54334773-C0EA238D-6BDB-48FA-B7BF-BAAC8D5F741CQ54399267-9EB80CCC-CEF7-4C64-A5D4-AB6E9A090646Q58586192-F7E69385-E3F5-4826-8BA5-B9053106A759
P2860
Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases
@en
type
label
Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases
@en
prefLabel
Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases
@en
P2860
P1476
Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases
@en
P2093
Fengchun Zhang
P2860
P304
P356
10.1016/J.PHARMTHERA.2013.03.003
P577
2013-03-24T00:00:00Z